Robert Gould is listed as an executive officer and director on 13 SEC Form D filings by 3 issuers between Feb 2016 and Nov 2023: Fulcrum Therapeutics, Inc. (Cambridge, MA — biotechnology — 2016–2020; $80M reported sold to 20 investors), HEMOSHEAR THERAPEUTICS, INC. (Charlottesville, VA — biotechnology — 2021–2023; $43.1M reported sold to 17 investors) and HEMOSHEAR THERAPEUTICS, LLC (Charlottesville, VA — biotechnology — 2016–2020; $2.64M reported sold to 26 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as executive officer and director, over about 7 years. Across those companies the filings report $125.7M sold in total.
2 of the issuers belong to the sponsor group Hemoshear Therapeutics (2 issuers, $5.78M reported sold, 2009–2023).
What this means A sponsor group is one team that sets up a new company for each deal. Hemoshear Therapeutics has 2 companies on file and $5.78M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 4 bankruptcy cases matching the name listed in Key records below.
What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 13 public filings for Robert Gould and found 11 differences: Form D filed 28 days after the first sale; Offering amount changed between filings; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.